Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023
Abstract Background The Chinese biosimilar industry has demonstrated rapid growth in recent years. Limited evidence is available about biosimilar uptake at the national level. This study aimed to assess biosimilar uptake in the case of trastuzumab and to explore potential factors influencing the bio...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
KeAi Communications Co., Ltd.
2024-10-01
|
| Цуврал: | Global Health Research and Policy |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://doi.org/10.1186/s41256-024-00372-z |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|